Vertex Pharmaceuticals Inc (VRTX) 126.94 $VRTX PDUFA

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 2:30 PM

Vertex Pharmaceuticals Inc (VRTX) 126.94 $VRTX

PDUFA date approaches for Kalydeco label expansion
Seeking Alpha - at Seeking Alpha - 1 hr 36 mins ago

VRTX: 126.94 (+2.94)

Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.90 (+0.13), VRTX: 126.94 (+2.94), CERU: 8.08 (+0.06), FOMX: 10.29 (+0.09), ONTX: 2.24 (-0.01), PFNX: 13.93 (-0.26), OMER: 23.99 (-1.22), PGNX: 6.58 (-0.51), SYN: 2.66 (-0.23), VCYT: 7.65 (-0.03), STEM: 1.17 (-0.07), APRI: 1.92 (-0.15), KPTI: 30.35 (+2.27)

Concert Pharma initiates Phase 1 study of deuterium-modified cystic fibrosis drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 7:09AM CDT

VRTX: 126.94 (+2.94), CNCE: 16.61 (+0.99)

After Yesterday's Decline of 1.21%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 11, 4:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $121.78 to a high of $124.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.90 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 126.94 (+2.94)

Vertex Pharmaceuticals Falls 1.21% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 11, 4:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $121.78 to a high of $124.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.90 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 126.94 (+2.94)

Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 11, 8:54AM CDT
Mergers and acquisitions show no sign of slowing down with AbbVie (ABBV) announcing that it will acquire Pharmacyclics(PCYC) for $21 billion.
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), GILD: 101.24 (+1.63), UTHR: 174.16 (+10.86), AMGN: 161.92 (+7.66), ABBV: 58.84 (+0.84), REGN: 447.67 (+18.29)

3 Biotech Stocks to Buy in March
Brian Orelli, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 11, 7:04AM CDT
"Our life is March weather, savage and serene in one hour." -- Ralph Waldo Emerson Substitute "biotechs" for "our life" and you have the investing version of Emerson's quote. Depending on how binary events go, they can certainly become savage...
VRTX: 126.94 (+2.94), ICPT: 296.33 (+14.95), CUR: 2.39 (-0.17)

Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses
at The Street - Tue Mar 10, 10:10AM CDT
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
VRTX: 126.94 (+2.94), SGEN: 39.07 (+0.76), HEB: 0.23 (unch)

Senior Housing Properties Trust: Price Appreciation Needs To Improve For This 7% Yielder
David Zanoni - at Seeking Alpha - Sun Mar 08, 12:15AM CST

VRTX: 126.94 (+2.94), SNH: 21.73 (+0.19)

Stocks Open Quietly Higher; Drugmakers Rally On AbbVie Deal
at Investor's Business Daily - Thu Mar 05, 9:44AM CST
Stocks opened higher in soft trade Thursday, helped by drugmakers moving higher on the heels of a $21 billion acquisition. The Nasdaq paced the market with a 0.5% gain. The Dow Jones industrial average gained 0.3%. The S&P 500 added 0.2%. The stock...
MNK: 126.09 (+1.97), VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), KR: 76.96 (+0.61), MYL: 60.84 (+1.08), COST: 149.75 (+0.47), ABBV: 58.84 (+0.84)

Today's Unusual Social Activity Stock: Vertex Pharmaceuticals (VRTX)
at The Street - Thu Mar 05, 8:53AM CST
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as an unusual social activity candidate
VRTX: 126.94 (+2.94)

AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST

VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), BMRN: 124.33 (+0.81), UTHR: 174.16 (+10.86), AMGN: 161.92 (+7.66), DYAX: 17.62 (+0.32), JNJ: 100.72 (+1.51), ESPR: 76.71 (+2.32), KITE: 62.70 (-0.39), RCPT: 149.38 (-0.04), PTCT: 73.28 (+0.01), ICPT: 296.33 (+14.95), ABBV: 58.84 (+0.84), JUNO: 52.11 (+2.62), SNY: 48.56 (+1.49)

Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 6.98 (-0.06), VRTX: 126.94 (+2.94), ISIS: 72.00 (+1.34), GILD: 101.24 (+1.63), AMGN: 161.92 (+7.66), ARNA: 4.76 (-0.05), CELG: 120.40 (+2.67)

BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District
PR Newswire - Mon Mar 02, 5:30AM CST
BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has recaptured approximately 313,000 square feet of space in the most dynamic and valuable life science real estate market in the world through the termination of Vertex Pharmaceuticals' leases on three properties in Cambridge, Massachusetts effective February 28, 2015. BioMed Realty will receive a $14 million termination fee from Vertex and will immediately begin to reposition the properties to meet the growing demand for lab space from new life science companies in this core innovation district.
BMR: 21.76 (+0.17), VRTX: 126.94 (+2.94)

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Feb 26, 10:07AM CST
Is Pharmacyclics (PCYC) up for sale? J&J and Novartis are rumored to be interested in acquiring the company.
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), VVUS: 3.01 (+0.19), AMGN: 161.92 (+7.66), ALKS: 66.80 (+0.41), REGN: 447.67 (+18.29), CELG: 120.40 (+2.67)

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer
at The Street - Wed Feb 25, 10:47AM CST
To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.
VRTX: 126.94 (+2.94), BMRN: 124.33 (+0.81), SHPG: 244.61 (+0.43), PTCT: 73.28 (+0.01)

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results
at The Street - Mon Feb 23, 10:06AM CST
Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.
VRTX: 126.94 (+2.94)

Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 10:02AM CST
Source: Gilead Sciences. All of the market's chatter surrounding Gilead Sciences ' and AbbVie 's hepatitis C drugs this past year may have you thinking that these companies have won the decades long battle against this tough-to-treat disease....
VRTX: 126.94 (+2.94), GILD: 101.24 (+1.63), CVS: 104.14 (+0.88), ABBV: 58.84 (+0.84)

3 Upcoming FDA Decisions We're Most Excited About
Motley Fool Staff - Motley Fool - Mon Feb 16, 7:08AM CST
Biotech stocks can often make big moves after reporting trial data, but it's FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they're most...
VRTX: 126.94 (+2.94), REGN: 447.67 (+18.29), CELG: 120.40 (+2.67)

Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 16, 6:41AM CST
Tiny biotech stock Achillion Pharmaceuticals reported what could be pretty big news for hepatitis C patients this week. The clinical stage biotechnology company released data showing that combining its ACH-3102 with Gilead Sciences ' Sovaldi...
VRTX: 126.94 (+2.94), GILD: 101.24 (+1.63), ACHN: 11.25 (-0.05), MRK: 57.08 (+0.88)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honoring Boston's Architects Changing the Game

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

SOCSA: The Future of Safety in Confined Spaces?

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Retirement Dreams Dashed: 61% Withdraw Early

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

NVIDIA Faces Legal Turbulence: CEO's Exit Sparks Chaos

Jensen Huang's Sudden Exit: A Barrage of Headlines In what feels like a blow delivered by a sledgehammer, NVIDIA is rocked by the abrupt resignation of its iconic co-founder and CEO, Jensen Huang. This isn't some quiet departure into the night. Nope, it's more like a cannonball being fired into the investor lounge, leaving a wreckage for all to navigate through. Huang's...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Sino Bio Speeds AI Drug Discovery with 4RISE Launch

AI Meets Real-World Validation In the world of cutting-edge biotech, Sino Biological is turning heads with its latest move. If you're in the game of AI-driven drug discovery, their new 4RISE™ high-throughput wet-lab validation services could be the breakthrough you've been waiting for. Why? Well, the promise of AI is dazzling, but it all boils down to how fast you can...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Fluence Energy Faces Class Action: Investor Insights

Investor Blues: Fluence Under the Weather If you've been keeping an eye on Fluence Energy (NASDAQ:FLNC), you're probably clutching your metaphorical pearls right now. Here's the scoop: on November 2, 2026, the stock took another nosedive—dropping nearly 9%—as the company announced that both CEO Julian Nebreda and CFO Ahmad Pasha had packed their bags. A leadership...

Missoula Inventor Offers Handy Phone Solution on the Move

Adjustable Convenience for the Modern Commuter When you're commuting or just lounging around, less hand strain and more comfort sounds like a no-brainer, right? Well, an inventive soul from Missoula, Montana, just might have cracked this little nut with a gizmo they're calling the COMMUTER PHONE. Imagine never having to juggle your phone during those bumpy moments on the...

PangeAI and Sky Blue Transform Data Center Decisions

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...